If you like what we do here, please click on our sponsor's banner. The device is trademarked under the name, ProstAlert. The patent will remain in effect for 20 years after initial filing, expiring September 10, 2017.
Prostate cancer is the most common form of non-skin cancers in men in the United States.
In 2000, an estimated 180,400 men were diagnosed with prostate cancer and an estimated 31,900 men died from prostate cancer according to the American Cancer Society s Cancer Facts and Figures 2000. The ProstAlert will be particularly useful in medical applications such as the detection of abnormalities in the human prostate gland. As applied to prostate examinations, the device with two temperature sensing elements may be affixed to the examiner s fingertip or to a mechanical probe to insert in the rectum. Upon withdrawal of the device from the rectum, the two temperature sensing elements will be examined in order to determine the temperature detected by each one. A significant temperature difference indicates the possibility of abnormal biological activity and the need for further diagnostic or medical procedures.